Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The analysis of liquidity ratios from April 2022 through March 2026 reveals a general contraction in short-term liquidity positions, characterized by a significant downward shift occurring at the end of 2022.
- Current Ratio
- The current ratio began at a robust level, peaking at 1.43 in October 2022, before experiencing a sharp decline to 0.99 by December 31, 2022. Following this drop, the ratio exhibited volatility with a notable recovery peak of 1.26 in December 2024. However, the trend stabilized at a lower threshold between 1.01 and 1.07 throughout 2025 and early 2026, indicating a transition toward a leaner liquidity posture where current assets only slightly exceed current liabilities.
- Quick Ratio
- A synchronized pattern is observed in the quick ratio, which fell from a high of 1.10 in October 2022 to 0.71 by the end of the same year. Although the ratio fluctuated between 0.70 and 0.96 in subsequent periods, it remained consistently below its 2022 baseline. The fact that the ratio remained primarily below 1.0 from late 2022 onward suggests a diminished ability to cover current liabilities using only the most liquid assets.
- Cash Ratio
- The cash ratio shows the most significant overall erosion, starting at 0.75 in October 2022 and dropping to 0.42 by December 31, 2022. While a temporary increase to 0.68 occurred in March 2025, the ratio trended downward again to 0.38 by March 2026. This trajectory highlights a reduced reliance on cash and cash equivalents for the immediate settlement of short-term obligations.
Overall, the simultaneous decline across all three metrics indicates a strategic or systemic shift in working capital management. The movement from a position of surplus liquidity in early 2022 to a tighter, more constrained environment by early 2026 suggests a reduced margin of safety regarding short-term financial commitments.
Current Ratio
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The short-term liquidity profile exhibits significant volatility over the analyzed period, characterized by an initial period of strong coverage followed by a sustained shift toward a tighter working capital margin. A transition is observed from a conservative liquidity position in early 2022 to a more lean operational approach throughout 2023, 2024, and 2025.
- Current Ratio Trends
- The current ratio began at a peak range of 1.39 to 1.43 between April and October 2022, indicating a robust ability to cover short-term obligations. A sharp contraction occurred by December 31, 2022, where the ratio fell to 0.99, marking the only instance in the period where current liabilities exceeded current assets. Following this dip, the ratio recovered and fluctuated primarily between 1.01 and 1.26. Toward the end of the period, the ratio stabilized at 1.03 as of March 29, 2026.
- Asset and Liability Dynamics
- Current assets showed marked fluctuations, reaching a maximum of 71,551 million US dollars in December 2024 before returning to a baseline range of 54,000 to 60,000 million US dollars. Concurrent with these movements, current liabilities peaked at 60,373 million US dollars in April 2023. The correlation between the growth in liabilities and the decrease in assets in late 2022 explains the temporary breach of the 1.0 threshold.
- Liquidity Stability and Management
- A pattern of stabilization is evident from 2024 through 2026, where the current ratio consistently remained near the 1.0 to 1.1 range. This suggests a strategic alignment of current assets with current liabilities, reducing idle liquidity while maintaining a marginal buffer to meet immediate financial obligations.
Quick Ratio
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Restricted cash | |||||||||||||||||||||||
| Marketable securities | |||||||||||||||||||||||
| Accounts receivable, trade, less allowances | |||||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position of the organization exhibited significant volatility between April 2022 and March 2026, transitioning from a position of surplus quick assets to a consistent deficit relative to current liabilities.
- Quick Ratio Trajectory
- An initial period of strengthening is observed from April 2022 to October 2022, with the quick ratio peaking at 1.10. This indicates a phase where liquid assets were sufficient to cover immediate obligations. However, a sharp contraction occurred by December 31, 2022, where the ratio fell to 0.71, marking a transition to a state where quick assets were no longer sufficient to cover current liabilities.
- Asset and Liability Dynamics
- The decline in the liquidity ratio in late 2022 was driven by a simultaneous decrease in total quick assets from approximately 50 billion USD to 39.7 billion USD and a surge in current liabilities from 45.5 billion USD to 55.8 billion USD. Throughout 2023, a modest recovery was noted, with the ratio fluctuating between 0.81 and 0.86, reflecting a temporary stabilization of the balance sheet.
- Short-Term Volatility and Peak Liquidity
- The period between March 2024 and December 2024 was characterized by instability, with the ratio dipping to 0.70 in September 2024 before rebounding to 0.78 in December 2024. A notable spike occurred on March 30, 2025, where the quick ratio reached 0.96, coinciding with a significant increase in total quick assets to 54.8 billion USD.
- Long-Term Liquidity Floor
- Following the peak in early 2025, a sustained downward trend is evident. From June 2025 through March 2026, the quick ratio remained constrained within a narrow range of 0.68 to 0.71. This suggests a systemic shift in the financial structure, as current liabilities remained consistently high—averaging above 50 billion USD—while quick assets failed to recover to previous peaks, stabilizing near 36 to 40 billion USD.
Cash Ratio
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Restricted cash | |||||||||||||||||||||||
| Marketable securities | |||||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the cash ratio reveals a general downward trajectory in immediate liquidity over the observed period. Starting from a peak of 0.75 in October 2022, the ratio experienced a sharp contraction by the end of that year and, despite intermittent recoveries, trended toward lower levels through March 2026.
- Cash Ratio Volatility
- The cash ratio exhibited significant fluctuations, beginning at 0.70 in April 2022 and reaching a maximum of 0.75 in October 2022. A sharp decline to 0.42 occurred by December 31, 2022. Although the ratio stabilized between 0.50 and 0.54 for much of 2023, it entered a period of further decline in 2025, reaching a low of 0.35 in June 2025 before marginally recovering to 0.38 by March 29, 2026.
- Cash Asset Dynamics
- Total cash assets showed inconsistent movement, with a notable spike to 38,781 million US dollars in March 2025. This peak was immediately followed by a steep reduction to 18,880 million US dollars by June 29, 2025. For the remainder of the period, cash assets remained significantly lower than the levels seen in 2022, generally oscillating between 18,000 and 22,000 million US dollars.
- Current Liability Trends
- Current liabilities demonstrated an overall increase, rising from 43,390 million US dollars in April 2022 to a peak of 60,373 million US dollars in April 2023. Following this peak, liabilities remained elevated, consistently staying above 50,000 million US dollars from June 2024 through March 2026. The combination of rising liabilities and fluctuating cash reserves contributed to the overall compression of the cash ratio.